North America Osteoarthritis Therapy Market Forecast to 2030 - Regional Analysis - by Therapy Type, Disease Indication, and End User

Description

List of Tables

The North America osteoarthritis therapy market was valued at US$ 7,873.88 million in 2022 and is expected to reach US$ 13,579.80 million by 2030; it is estimated to register a CAGR of 7.1% from 2022 to 2030.

More Effective Treatment Options Fuels North America Osteoarthritis Therapy Market

Currently, there is no cure for OA. A group of clinical research scientists, through clinical trials, reveal that they are developing innovative treatment target options that can stop the progression of OA. For example, in November 2021, LG Chem company announced the initiation of a clinical trial for next-generation new drugs to treat arthritis. Additionally, in October 2021, Pacira BioSciences, Inc. announced the acquisition of Flexion Therapeutics to treat non-opioid pain management "ZILRETTA". The drug approved in 2017 is the first and only approved treatment for OA knee pain utilizing extended-release microsphere technology.

In September 2023, Sorrento Therapeutics, Inc. announced positive Phase 2 top-line clinical trial results for the "Resiniferatoxin (RTX) program". The Phase 2 trial is a multi-center, double-blind, placebo, and active-controlled study assessing the efficacy and safety of several dose groups of RTX to manage pain in patients with moderate-to-severe OAK. Also, Sorrento decided to include an active approved competitor drug, "Zilretta," in the current clinical trial protocol.

North America Osteoarthritis Therapy Market Overview

North America osteoarthritis therapy market is segmented as US, Canada, and Mexico. Fast product launches by the US Food and Drug Administration (FDA) for osteoarthritis drugs and government support for accelerating product launches are the most impacting factors for the market growth. According to the statistics revealed in the Centers for Disease Control and Prevention (CDC) report, osteoarthritis (OA) is the most common form of arthritis, affecting 32.5 million US adults. Additionally, the Osteoarthritis (OA) Action Alliance report reveals that the overall economic burden associated with OA in the US is estimated at US$ 136.8 billion annually. Further, the American Roentgen Ray Society ARRS report reveals that the lifetime risk of OA is 50%, and it is estimated that by 2040, ~78 million (26%) US adults will have OA.

Further, new product approvals by the manufacturers aiming for non-pharmacology therapy for OA pain further influence market growth. For instance, in June 2021, CyMedica Orthopedics announced receiving approval for the "Intellihab System," a noninvasive modality for knee osteoarthritis pain by the US Food and Drug Administration (USFDA). The new product launch is a therapeutic and digital-based ecosystem that is designed to treat OA pain with a debilitating osteoarthritis disease. Therefore, new non-pharmacology therapy intended for OA pain focusing on reducing dependency on therapeutics is a key factor for fueling the growth of the osteoarthritis therapy market.

North America Osteoarthritis Therapy Market Revenue and Forecast to 2030 (US$ Million)

North America Osteoarthritis Therapy Market Segmentation

The North America osteoarthritis therapy market is categorized into therapy type, disease indications, end user, and country.

Based on therapy type, the North America osteoarthritis therapy market is segmented into transcutaneous electrical nerve stimulation (TENS), occupational therapy, physical therapy, platelet-rich plasma (PRP) therapy & stromal vascular fraction, prolotherapy, and others. The physical therapy segment held the largest market share in 2022.

In terms of disease indications, the North America osteoarthritis therapy market is segmented into knee osteoarthritis, spine osteoarthritis, foot and ankle osteoarthritis, shoulder osteoarthritis, hand osteoarthritis, and others. The knee osteoarthritis segment held the largest share of North America osteoarthritis therapy market in 2022.

Based on end user, the North America osteoarthritis therapy market is categorized into hospitals and clinics, specialty clinics, ambulatory surgical center, homecare, and others. The homecare segment held the largest share of North America osteoarthritis therapy market in 2022.

By country, the North America osteoarthritis therapy market is segmented into the US, Canada, and Mexico. The US dominated the North America osteoarthritis therapy market share in 2022.

Vision Quest Industries Inc, Dr PRP USA LLC, Zimmer Biomet Holdings Inc, DePuy Synthes Inc, Bioventus Inc, Omron Healthcare Inc, Exactech Inc, and Medi GmbH & Co KG are some of the leading companies operating in the North America osteoarthritis therapy market.

Product Code: BMIRE00030514

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Osteoarthritis Therapy Market Landscape

4.1 Pipeline Analysis
- 4.1.1 Clinical Trial Pipeline Analysis

5. North America Osteoarthritis Therapy Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Prevalence of Osteoarthritis
- 5.1.2 Innovative Therapy Options Reducing Dependency on Medications
5.2 Market Restraints
- 5.2.1 Product Recall
5.3 Market Opportunities
- 5.3.1 Availability of Regenerative Medicine
5.4 Future Trends
- 5.4.1 More Effective Treatment Options
5.5 Impact of Drivers and Restraints:

6. Osteoarthritis Therapy Market - North America Market Analysis

6.1 Overview
- 6.1.1 Osteoarthritis Therapy Market Revenue (US$ Million), 2020-2030

7. North America Osteoarthritis Therapy Market Analysis - by Therapy Type

7.1 Overview
7.2 Transcutaneous Electrical Nerve Stimulation (TENS)
- 7.2.1 Overview
- 7.2.2 Transcutaneous Electrical Nerve Stimulation (TENS): Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Occupational Therapy
- 7.3.1 Overview
- 7.3.2 Occupational Therapy: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Physical Therapy
- 7.4.1 Overview
- 7.4.2 Physical Therapy: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Platelet-Rich Plasma Therapy and Stromal Vascular Fraction
- 7.5.1 Overview
- 7.5.2 Platelet-Rich Plasma Therapy and Stromal Vascular Fraction: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Prolotherapy
- 7.6.1 Overview
- 7.6.2 Prolotherapy: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Osteoarthritis Therapy Market Analysis - by Disease Indication

8.1 Overview
8.2 Knee Osteoarthritis
- 8.2.1 Overview
- 8.2.2 Knee Osteoarthritis: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Spine Osteoarthritis
- 8.3.1 Overview
- 8.3.2 Spine Osteoarthritis: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Foot and Ankle Osteoarthritis
- 8.4.1 Overview
- 8.4.2 Foot and Ankle Osteoarthritis: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Shoulder Osteoarthritis
- 8.5.1 Overview
- 8.5.2 Shoulder Osteoarthritis: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Hand Osteoarthritis
- 8.6.1 Overview
- 8.6.2 Hand Osteoarthritis: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.7 Others
- 8.7.1 Overview
- 8.7.2 Others: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Osteoarthritis Therapy Market Analysis - by End User

9.1 Overview
9.2 Hospitals and Clinics
- 9.2.1 Overview
- 9.2.2 Hospitals and Clinics: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Specialty Clinics
- 9.3.1 Overview
- 9.3.2 Specialty Clinics: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
- 9.4.1 Overview
- 9.4.2 Ambulatory Surgical Centers: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Homecare
- 9.5.1 Overview
- 9.5.2 Homecare: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Osteoarthritis Therapy Market - Country Analysis

10.1 North America Market Overview
- 10.1.1 North America: Osteoarthritis Therapy Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.1 United States: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.1.1 Overview
    - 10.1.1.1.2 United States: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.1.3 United States: Osteoarthritis Therapy Market Breakdown, by Therapy Type
    - 10.1.1.1.4 United States: Osteoarthritis Therapy Market Breakdown, by Disease Indication
    - 10.1.1.1.5 United States: Osteoarthritis Therapy Market Breakdown, by End User
  - 10.1.1.2 Canada: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.2.1 Overview
    - 10.1.1.2.2 Canada: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.2.3 Canada: Osteoarthritis Therapy Market Breakdown, by Therapy Type
    - 10.1.1.2.4 Canada: Osteoarthritis Therapy Market Breakdown, by Disease Indication
    - 10.1.1.2.5 Canada: Osteoarthritis Therapy Market Breakdown, by End User
  - 10.1.1.3 Mexico: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.3.1 Overview
    - 10.1.1.3.2 Mexico: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.3.3 Mexico: Osteoarthritis Therapy Market Breakdown, by Therapy Type
    - 10.1.1.3.4 Mexico: Osteoarthritis Therapy Market Breakdown, by Disease Indication
    - 10.1.1.3.5 Mexico: Osteoarthritis Therapy Market Breakdown, by End User

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in the osteoarthritis therapy market
11.3 Organic Developments
- 11.3.1 Overview
11.4 Inorganic Developments
- 11.4.1 Overview

12. Company Profiles

12.1 Vision Quest Industries Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Dr PRP USA LLC
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Zimmer Biomet Holdings Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 DePuy Synthes Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Bioventus Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Omron Healthcare Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Exactech Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Medi GmbH & Co KG
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments

13. Appendix

13.1 About the Insight Partners